barda
(2)
The Chicago lab teaching hospitals to read your blood before sepsis reads you
Sepsis kills more Americans than all cancers combined and hides in plain sight. Prenosis spent a decade building a biobank and an algorithm to catch it in the first 24 hours - and got the FDA to say yes.
Paratek Pharmaceuticals
Paratek Pharmaceuticals is a Boston-based commercial-stage biopharmaceutical company built on tetracycline chemistry to fight drug-resistant bacterial infections. Its flagship antibiotic NUZYRA (omadacycline) is a once-daily oral and IV broad-spectrum drug approved by the FDA in 2018 for community-acquired bacterial pneumonia and acute skin infections, and it is also being developed under a major BARDA contract as a national-stockpile countermeasure against pulmonary anthrax. Paratek also originated SEYSARA (sarecycline) for acne. Now privately held by Gurnet Point Capital and Novo Holdings after a 2023 acquisition, the company positions itself as a defender of public health against the slow-moving pandemic of antimicrobial resistance.